



NORMON

Experience and
technology committed
to healthcare



Our vocation towards the pharmaceutical sector has helped our company grow

At the end of the 1930s, two small laboratories were founded almost at the same time: Orto in Seville (1937) and Normon in Madrid (1938). In 1958, both companies merged under the name Laboratorios Normon, with its headquarters in Madrid. A new company which made giant leaps in the sector over the following decades, and which, through constant innovation and continuous development became the company NORMON is today.

In the late 1990s, Normon launched the first authorized generic medicinal products in our country (1997), consolidating its current undisputed leading position within the Spanish market of generic drugs.

Nowadays, Normon has one of the largest and most modern drug manufacturing laboratories, with more than 86,000 m², located in Tres Cantos, Madrid, which was inaugurated in 2006 by Her Majesty Queen Sofia of Spain.

Normon is a large Spanish business group that has managed to become one of the first manufacturers of medicines within Europe. The success of a true pharmaceutical vocation with 80 years of history, developing, manufacturing and marketing high-quality medicines, thanks to a business strategy of innovation, constant reinvestment of benefits, diversification and internationalization.



Establishment of Laboratorios Normon in Madrid (Spain).
Headquarters in Madrid.

1938

1937

Establishment of Laboratorios Orto in Sevilla (Spain).





Start of the international expansion.
1975



Launch of the First Generic Drug in the Spanish Market.
1997



Launch of the new OTC Division.
2010



Approval by FDA (Food and Drug Administration).
2016



1958
Merger of both companies under the name **Laboratorios Normon**. Headquarters in Madrid.



1992
Launch of the **Dental Division** and marketing of **Ultracain**.



2006
Her Majesty Queen Sofia of Spain inaugurates the new facilities in Tres Cantos, Madrid.



2011
Normon expands its **facilities** to 86,000 m².



2017
Normon celebrates **80 years**.

Reference manufacturing plant within Europe

Normon's facilities, located in Tres Cantos, in the north of Madrid, occupy a total built area of 86,000 m², and are equipped with the latest technology. The new Normon Complex is undoubtedly one of Europe's most modern laboratories for the manufacture of pharmaceutical products, as well as an example of technological efficiency committed to healthcare.

- 1 Manufacture of oral and injectable products
- 2 Manufacture of penicillanic antibiotics
- 3 Manufacture of cephalosporin antibiotics
- 4 Manufacture of cytotoxic medicines and high pharmaceutical activity
- 5 Manufacture - Packaging
- 6 Automated warehouse for storing finished products and packaging materials
- 7 Picking and Issuing
- 8 Warehouse for raw materials
- 9 Manufacture of liquid and freeze-dried vials
- 10 Quality control + office premises
- 11 R&D and innovation + office premises





1

2

3

4

5

6

5

7

8

9

NORMON

Technological efficiency committed to healthcare

The manufacturing plant is designed with an innovative style of modular structures with independent areas within the plant. In this way, maximum productivity is achieved, with a great versatility for the manufacture of medicines, both regarding the amount of different pharmaceutical forms and the variety of presentations that are elaborated.

Our facilities consist of a plant for developing pharmaceutical drugs, a quality control laboratory and four independent manufacturing zones:

- General manufacture: oral and injectable products.
- Manufacture of penicillin antibiotics: oral and injectable products.
- Manufacture of cephalosporin antibiotics: oral and injectable products.
- Manufacture of cytotoxic and high activity products: oral and injectable products.

Oral forms: tablets, coated tablets, pills, capsules, syrups, solutions, extemporaneous suspensions and sachets.

Injectable forms: liquid vials, powder vials, freeze-dried vials, ampoules, polypropylene bags for infusion and cartridges (cylindrical ampoules for dental anesthetics).



Quality and high manufacturing capacity

The continuous improvement of the facilities ensures efficient production management, modular and high performance.

Normon's manufacturing plant has a high and flexible production capacity that can be increased according to needs.





Manufacturing lines

Manufacture of oral medicinal products

Granulation equipment (dry + wet granulation)	11
Compression equipment	16
Coating equipment	9
Capsule manufacturing equipment	5
Sachet lines	5
Topical / oral liquid lines	1
Powder filling lines	1

Manufacturing of injectable products

Dental cartridge filling lines	2
Liquid/lyophilized vial filling lines	4
Lyophilizers	11
Powder vial filling lines	2
Infusion bag filling lines	1
Ampoule filling lines	2
Automatic inspection machine for injectable products	10

Packaging

Packaging lines	41
-----------------	----

Robotic storage (pallets)	20.000
---------------------------	--------

The value of a great team

After all its years of experience in the pharmaceutical industry, Normon has grown steadily at all levels, thanks to the know-how and hard work of its highly qualified team. The company's workforce, comprised of more than 1,800 people, is one of the basic pillars on which its remarkable growth and development are built.

Normon's staff is one of the company's greatest assets. Continuous training, specialization, appropriate working facilities and compliance with the rules of each department have yielded a highly qualified workforce able to grow with the company.





The value of R&D and innovation

Normon's commitment to research and innovation is the foundation on which the company's business strategy is built, enabling it to offer products and services that meet our patients' highest expectations (and those of our society in general).

The company reinforces its constant search for innovation thanks to its continued relationship with institutions such as the Spanish National Research Council (CSIC), hospitals and universities, with which it undertakes numerous research programs. Its scientific and innovative profile led Normon to be the first company to develop the first generic drugs in Spain in the 1990s.

Since then, it has been at the forefront of Spain's generic drug industry, both in terms of the number of bioequivalence studies and the amount of active ingredients researched. The Intellectual Property and R&D Departments guarantee that all its products are launched in full compliance with requirements relating to patents as well as the registration of patents covering Normon's innovation.

As it is to be expected, Normon has achieved certification in Good Laboratory Practice (GLP), in accordance with Directive 2004/9/EC with regards to the development of new products, as well as the certification in Good Manufacturing Practice (GMP).

The value of quality

The Quality Assurance Department is another pillar on which Normon is built. The company is fully committed to the high quality of its products and ensures that this quality is maintained throughout the entire production process, from the purchase of raw materials to the packaging and dispatch of the products.

Quality is therefore ensured through the implementation of controls at each stage of the drug manufacturing process by highly qualified staff with the most advanced tools and equipment.

Normon has achieved ISO 9001 Quality Management Certification and ISO 14001 Environmental Management Certification in the Design, Manufacturing and Distribution of pharmaceutical products.

ISO 9001:2008 certification is proof of the quality, safety and reliability of Normon's products. It is also a recognition of its work, commitment and ability to meet the needs and expectations of its customers and employees, as well as an indicator of the company's firm commitment to the planning, control and continuous improvement of quality management.

Additionally, ISO 14001:2004 certification demonstrates Normon's initiative in the implementation and maintenance of an appropriate environmental management system to ensure that its activities and actions in the design, manufacture and distribution of pharmaceutical products have a minimal impact on the environment.

Furthermore, Normon also has the ISO 13485:2003 for the Production, Sale and Distribution of medical devices.



FDA approval

In 2016, the US FDA (Food and Drugs Administration) granted Normon authorization to manufacture sterile liquid vials at its facilities in Spain.

Our commitment to society

Normon is a socially conscious company. The manufacture of top quality pharmaceutical products for the entire community, solidarity towards the worst-off members of society and protection of the environment are primary objectives of the company.

Acts of solidarity

For more than 10 years, Normon has signed an agreement with the Fundación Reina Sofía for the provision of humanitarian aid, both at a national level and to be sent mainly to Central America and the Caribbean. The agreement aims to make essential medication available to those who most need it, free of charge.

Normon also cooperates with foundations such as the Fundación Numen (since 2011), dedicated to people affected by cerebral paralysis and neurological damage, and the Fundación Juan XXIII (since 2005), dedicated to integrating disabled people into the workforce and society.





Committed to the environment

(ISO 14001 Environmental Management Certification)

Normon has implemented an Integrated Quality and Environment System. It carries out permanent controls which ensure the compliance of environmental laws and legislation. Normon encourages environmental awareness among its workers, and prevents and reduces contamination, with the objective of minimizing any possible negative impacts. The manufacturing plant has implemented, for example, a sophisticated water-recycling system which enables the reuse of more than 24,000 liters of water daily.

Leader in quality generic pharmaceutical products

In 1990, Laboratorios Normon began to develop Generic Pharmaceutical Products. Seven years later, it was also the first pharmaceutical company to market the first three generic drugs authorized in Spain. Since then, the company has remained at the forefront as leader in the domestic generic drug market by making significant and on-going investment in R&D and innovation, which ensures the pharmaceutical quality is available to many more people.

Normon is now the leading manufacturer of generic drugs in Spain, as it offers the widest product range on the domestic market, comprised of more than 200 active ingredients which are marketed in over 1,000 presentations. It is present in the main therapeutic areas of the market, providing cardiovascular, anti-infective and anti-ulcer drugs; medication for the nervous system, analgesics, anti-inflammatory and anti-gout drugs, antihistamines, lipid lowering, mucolytic, oncological and anti-diabetic medication, etc.



661069.50

Atorvastatina
Normon 40 mg

comprimidos recubiertos con película EFG

Via oral
28 comprimidos



Hospital Division

Normon's Hospital Division is present in practically all clinics and hospitals in Spain, and offers the widest range of oral and parenteral products used in healthcare facilities.

Normon was the first company to adapt its products for hospital use by manufacturing medication in unit doses, thus facilitating the work of healthcare professionals in the hospital sector.

It has recently consolidated its position as the leading provider of medication to hospitals in Spain. It supplies more than 19% of all hospital medication in the country (Source: IMS data).





Dental Division

Normon's Dental Division was established in 1992, when the company began to manufacture and market Ultracain, the most prestigious anesthetic in the odontology field. Thanks to its wide line of dental anesthetic products, Normon is present in more than 53% of the market, which makes the laboratory the current leader within this field.

The manufacture of this medication in cartridges (cylindrical ampoules), which has increased the company's production capacity and enabled it to export its products to other countries, requires the facilities to count on the most modern technology.

In addition to anesthetics and prescription medication (mainly antibiotics, analgesics and anti-inflammatory drugs), Normon has also made a wide range of top-quality products available to dental professionals, such as needles and syringes, restoration and impression materials, disinfectant and teeth whitening products and a complete line of biomaterials for bone regeneration.





OTC Division

In an endeavor to enhance our quality of life, adopt healthy habits and prevent disease, self-care has become an extremely important concern of society today. Nowadays, we have a greater personal responsibility towards one's health and quality of life.

Normon strives to promote responsible health care by offering a wide range of OTC products. Products that meet diverse needs and that act effectively improving people's quality of life. For this reason, the role of the health professional is essential in order to inform, advise and provide the best solutions in an approachable way, for the responsible use by the general public. There are several OTC Normon areas.

normoefp[®] medication to relieve the symptoms of minor ailments, such as analgesics, antitussives, antiseptics, etc.

normocalm[®] products for pain relief and inflammation.

normocare[®] products for the care of the five senses.

normodent[®] products for a correct dental hygiene.

normogel[®] products for burn relief.

normomar[®] products for a complete nasal and eye care and hygiene.

normopic[®] insect repellents and pain relievers.

normovisión[®] eye care.

normovital[®] food supplements to help maintain or restore vitality.





International Division

More than 40 years ago, Normon began to export its products worldwide. Nowadays, its cross-border commercial activity is essential in the growth of the company. Normon continues to consolidate its international expansion project by seeking and strengthening new markets to commercialize its medicinal products and also by licensing and manufacturing for other companies.

Normon currently works with most European countries, with license, manufacturing and distribution agreements. It has a strong presence in Central and South America, and it is in the process of introducing its products in the USA, (the manufacturing plant having already been approved by the US state agency, FDA), Canada and Mexico.

Likewise, Normon markets its products in many countries within the African continent and Middle East countries, and it is also consolidating its expansion project in Asia, an area with a high potential market. Normon is also present in Australia and New Zealand.





Normon, 80 years committed to health







NORMON

Ronda de Valdecarrizo, 6
28760 Tres Cantos, Madrid, España
Tel.: +34 91 806 52 40
www.normon.es

